Results 151 to 160 of about 21,074 (263)

Selecting between pharmacotherapy and bariatric surgery in East Asia

Journal of Diabetes Investigation, EarlyView.
Yamato Keidai, Junji Fujikura, Hiroto Minamino, Kohei Takesue, Daisuke Yabe   +4 more
wiley   +1 more source

Intestinal epithelial injury and inflammation after physical work in temperate and hot environments in older men with hypertension or type 2 diabetes

Experimental Physiology, EarlyView.
Abstract We tested whether older adults with well‐controlled type 2 diabetes or hypertension, compared with age‐matched adults without chronic disease, exhibit greater intestinal damage, microbial translocation and inflammation during exertional heat stress.
Ben J. Lee, Tessa R. Flood, Sophie L. Russell, James J. McCormick, Kelli E. King, Naoto Fujii, Tatsuro Amano, Sean Notley, Glen P. Kenny   +8 more
wiley   +1 more source

Changes in incretin hormone concentrations after pancreaticoduodenectomy: a systematic review and exploratory meta-analysis. [PDF]

Front Endocrinol (Lausanne)
Grząsiak-Kraj O, Kraj T, Poznański K, Szmiel A, Strzelczyk J.   +4 more
europepmc   +1 more source

Semaglutide impacts skeletal muscle to a similar extent as caloric restriction in mice with diet‐induced obesity

The Journal of Physiology, EarlyView.
Abstract figure legend Four weeks of semaglutide treatment causes significant reductions in total body weight, fat mass, lean mass, and grip strength in mice with diet induced obesity. Mice treated with semaglutide lost a greater amount of total body weight and fat mass compared to mice fed fed a calorie matched diet.
S. Jeromson, B. Baranowski, M. Akcan, B. D. Waters, K. Eisner, A. Bellucci, S. Trang, A. Abolhassani, M. A. Tello‐Palencia, A. Schweitzer, B. Stefanska, C. J. Mitchell, David C. Wright   +12 more
wiley   +1 more source

Sex‐specific metabolic responses to glucagon receptor agonism and modulation of the FGF21‐glucagon axis in female mice

The Journal of Physiology, EarlyView.
Abstract figure legend Therapies targeting the glucagon receptor are being explored for obesity treatment, yet most preclinical studies remain male biased. In this study, Merrild and Johansen et al. show that in diet‐induced obese wild‐type mice a long‐acting glucagon analogue (LA‐Gcg) elicits sexually dimorphic effects on weight loss, food intake ...
Christoffer Merrild, Valdemar Brimnes Ingemann Johansen, Christoffer Clemmensen, Pablo Ranea‐Robles   +3 more
wiley   +1 more source

Evolution of incretin-based therapies: From GLP-1 monotherapy to dual and triple agonists: A new era in metabolic therapy. [PDF]

Indian J Med Res
Gupta M, Shukla J.
europepmc   +1 more source

Adaptations of glucagon‐like peptide‐1 receptor agonist‐induced weight loss, drivers of weight regain and future directions of therapeutics

The Journal of Physiology, EarlyView.
Abstract figure legend During GLP‐1RA treatment reduced appetite and energy intake, delayed gastric emptying, decreased visceral fat mass and improved glycaemic control contribute to weight loss. After treatment cessation these benefits are partially or completely reversed, resulting in weight regain, accompanied by increased appetite and energy intake,
Camille E. M. Piguet, Rosie Nucci, Jacqueline L. Beaudry   +2 more
wiley   +1 more source

Metabolic Dysfunction-Associated Steatotic Liver Disease and Incretin Receptor Agonists: A Metabolic Approach to Halting Liver Disease Progression. [PDF]

Medicina (Kaunas)
Abenavoli L, Loricchio AG, Lopez I, Morano D, Ismaiel A, Dumitrascu DL, Luzza F.   +6 more
europepmc   +1 more source

When Glycaemic Control Comes Too Fast: Treatment‐Induced Neuropathy of Diabetes and Charcot Neuro‐Osteoarthropathy as Emerging Iatrogenic Complications of Rapid Metabolic Correction

Diabetes/Metabolism Research and Reviews, Volume 42, Issue 6, September 2026.
ABSTRACT Purpose of Review Diabetes therapeutics can lower glycated haemoglobin (HbA1c) by several percentage points within weeks. While long‐term microvascular risk is reduced by improved glycaemia, abrupt metabolic transitions may destabilise tissues adapted to chronic hyperglycemia.
Dured Dardari
wiley   +1 more source

Weight Loss‐Dependent Changes in Body Composition and Bone Health in People With Obesity and Type 1 Diabetes Treated With Liraglutide, Semaglutide, or Tirzepatide

Diabetes/Metabolism Research and Reviews, Volume 42, Issue 6, September 2026.
ABSTRACT Aims This study examined changes in body composition and bone mineral density (BMD) over 12 months in people with obesity and type 1 diabetes (T1D) treated with a GLP‐1 receptor agonist alone (GLP‐1RA) or a dual glucose‐dependent insulinotropic polypeptide (GIP/GLP‐1RA).
Ebaa Al Ozairi, Mohammad Irshad, Jumana Alkandri, Anant Mashankar, Stuart R. Gray, Carel W. le Roux   +5 more
wiley   +1 more source